Onc Now: AI, Immunotherapy, and the Next Wave of Cancer Trials - European Medical Journal

This site is intended for healthcare professionals

Onc Now: AI, Immunotherapy, and the Next Wave of Cancer Trials

Oncology

Onc Now 

In this episode of Onc Now, we explore the challenges of translating early-phase oncology research into meaningful clinical benefit. Victor Moreno Garcia discusses why so many promising therapies fail in Phase I–III trials, the complexity of the tumour microenvironment, and the evolving role of biomarkers, AI, and combination strategies in improving success rates. The conversation also highlights advances in cell therapy for solid tumours, the future of precision oncology, and how global factors are shaping cancer research.

Apple | Spotify | Amazon Music | Youtube

 

Speaker bio: 

onc

 

 

Victor Moreno Garcia is a medical oncologist with over a decade of experience in early-phase clinical trials and cancer drug development. He obtained his medical degree from Complutense University of Madrid, Spain, before completing his specialist training in medical oncology at La Paz University Hospital, Madrid. Alongside this, he earned a master’s degree in molecular oncology from the Spanish National Cancer Research Centre (CNIO), Madrid, and a PhD focused on rectal cancer.

 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.